# NaÃ-r RodrÃ-guez-Hornedo

List of Publications by Year
in descending order



| 59 | 6,658 | 126907 | 149698 |
|---|---|---|---|
| papers | citations | 33 h-index | 56 g-index |

| 60 | 60 | 60 | 3667 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Gas-Assisted Cocrystal Desublimation. Crystal Growth and Design, 2022, 22, 1528-1532. | 3.0 | 1 |
| 2 | Synchronization of Cocrystal Dissolution and Drug Precipitation to Sustain Drug Supersaturation. Molecular Pharmaceutics, 2022, 19, 2765-2775. | 4.6 | 7 |
| 3 | Stability of Pharmaceutical Co-Crystals at Humid Conditions Can Be Predicted. Pharmaceutics, 2021, 13, 433. | 4.5 | 11 |
| 4 | Co-Crystal Screening by Vapor Sorption of Organic Solvents. Crystal Growth and Design, 2021, 21, 4445-4455. | 3.0 | 4 |
| 5 | Cocrystal Solubility Advantage and Dose/Solubility Ratio Diagrams: A Mechanistic Approach To Selecting Additives and Controlling Dissolutionâ€“Supersaturationâ€“Precipitation Behavior. Molecular Pharmaceutics, 2020, 17, 4286-4301. | 4.6 | 19 |
| 6 | The role of pH and dose/solubility ratio on cocrystal dissolution, drug supersaturation and precipitation. European Journal of Pharmaceutical Sciences, 2020, 152, 105422. | 4.0 | 30 |
| 7 | Cocrystal Solubility Advantage Diagrams as a Means to Control Dissolution, Supersaturation, and Precipitation. Molecular Pharmaceutics, 2019, 16, 3887-3895. | 4.6 | 35 |
| 8 | Posaconazole Cocrystal with Superior Solubility and Dissolution Behavior. Crystal Growth and Design, 2019, 19, 6592-6602. | 3.0 | 47 |
| 9 | Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses. Pharmaceutics, 2019, 11, 122. | 4.5 | 17 |
| 10 | An Expandable Mechanopharmaceutical Device (1): Measuring the Cargo Capacity of Macrophages in a Living Organism. Pharmaceutical Research, 2019, 36, 12. | 3.5 | 8 |
| 11 | Mechanistic Analysis of Cocrystal Dissolution, Surface pH, and Dissolution Advantage as a Guide for Rational Selection. Journal of Pharmaceutical Sciences, 2019, 108, 243-251. | 3.3 | 12 |
| 12 | Cocrystals Mitigate Negative Effects of High pH on Solubility and Dissolution of a Basic Drug. Crystal Growth and Design, 2018, 18, 1358-1366. | 3.0 | 42 |
| 13 | Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS) Tj ETQq1 1 0.784314 rgBT /Overl<br>Journal of Pharmaceutical Sciences, 2018, 115, 258-269. | 4.0 | 43 |
| 14 | Mechanistic Basis of Cocrystal Dissolution Advantage. Journal of Pharmaceutical Sciences, 2018, 107, 380-389. | 3.3 | 17 |
| 15 | Understanding the Differences Between Cocrystal and Salt Aqueous Solubilities. Journal of Pharmaceutical Sciences, 2018, 107, 113-120. | 3.3 | 34 |
| 16 | Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humansâ€”Part 1: Fasted State Conditions. Molecular Pharmaceutics, 2018, 15, 5454-5467. | 4.6 | 21 |
| 17 | Tadalafilâ€“Malonic Acid Cocrystal: Physicochemical Characterization, pH-Solubility, and Supersaturation Studies. Crystal Growth and Design, 2018, 18, 4378-4387. | 3.0 | 31 |
| 18 | Multidrug Cocrystal of Anticonvulsants: Influence of Strong Intermolecular Interactions on Physiochemical Properties. Crystal Growth and Design, 2017, 17, 5012-5016. | 3.0 | 58 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5. Advanced Drug Delivery Reviews, 2016, 101, 143-166. | 13.7 | 160 |
| 20 | Turning Liquid Propofol into Solid (without Freezing It): Thermodynamic Characterization of Pharmaceutical Cocrystals Built with a Liquid Drug. Crystal Growth and Design, 2016, 16, 6547-6555. | 3.0 | 20 |
| 21 | Mechanistic Analysis of Cocrystal Dissolution as a Function of pH and Micellar Solubilization. Molecular Pharmaceutics, 2016, 13, 1030-1046. | 4.6 | 36 |
| 22 | Cocrystal Solubilization in Biorelevant Media and its Prediction from Drug Solubilization. Journal of Pharmaceutical Sciences, 2015, 104, 4153-4163. | 3.3 | 21 |
| 23 | Cocrystal Transition Points: Role of Cocrystal Solubility, Drug Solubility, and Solubilizing Agents. Molecular Pharmaceutics, 2015, 12, 3535-3546. | 4.6 | 47 |
| 24 | Pharmaceutical cocrystals and poorly soluble drugs. International Journal of Pharmaceutics, 2013, 453, 101-125. | 5.2 | 501 |
| 25 | Tailoring aqueous solubility of a highly soluble compound via cocrystallization: effect of coformer ionization, pHmax and soluteâ€“solvent interactions. CrystEngComm, 2012, 14, 4801. | 2.6 | 71 |
| 26 | pH-Dependent Solubility of Indomethacinâ€“Saccharin and Carbamazepineâ€“Saccharin Cocrystals in Aqueous Media. Molecular Pharmaceutics, 2012, 9, 2605-2612. | 4.6 | 97 |
| 27 | Polymorphs, Salts, and Cocrystals: Whatâ€™s in a Name?. Crystal Growth and Design, 2012, 12, 2147-2152. | 3.0 | 767 |
| 28 | Correction for Polymorphs, Salts and Cocrystals: Whatâ€™s in a Name?. Crystal Growth and Design, 2012, 12, 4290-4291. | 3.0 | 17 |
| 29 | Dependence of cocrystal formation and thermodynamic stability on moisture sorption by amorphous polymer. CrystEngComm, 2011, 13, 1181-1189. | 2.6 | 29 |
| 30 | Engineering cocrystal thermodynamic stability and eutectic points by micellar solubilization and ionization. CrystEngComm, 2011, 13, 5409. | 2.6 | 32 |
| 31 | Engineering cocrystal solubility, stability, and pHmax by micellar solubilization. Journal of Pharmaceutical Sciences, 2011, 100, 5219-5234. | 3.3 | 42 |
| 32 | Transformation Pathways of Cocrystal Hydrates When Coformer Modulates Water Activity. Journal of Pharmaceutical Sciences, 2010, 99, 3977-3985. | 3.3 | 37 |
| 33 | Cocrystal Eutectic Constants and Prediction of Solubility Behavior. Crystal Growth and Design, 2010, 10, 1028-1032. | 3.0 | 117 |
| 34 | Effect of Micellar Solubilization on Cocrystal Solubility and Stability. Crystal Growth and Design, 2010, 10, 2050-2053. | 3.0 | 52 |
| 35 | Solvent Effects on the Crystallization and Preferential Nucleation of Carbamazepine Anhydrous Polymorphs: A Molecular Recognition Perspective. Organic Process Research and Development, 2009, 13, 1291-1300. | 2.7 | 41 |
| 36 | Factors that influence the spontaneous formation of pharmaceutical cocrystals by simply mixing solid reactants. CrystEngComm, 2009, 11, 493-500. | 2.6 | 70 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Role of Cocrystal and Solution Chemistry on the Formation and Stability of Cocrystals with Different Stoichiometry. Crystal Growth and Design, 2009, 9, 889-897. | 3.0 | 148 |
| 38 | Cocrystals and Salts of Gabapentin: pH Dependent Cocrystal Stability and Solubility. Crystal Growth and Design, 2009, 9, 378-385. | 3.0 | 164 |
| 39 | Analysis of 50 Crystal Structures Containing Carbamazepine Using the Materials Module of Mercury CSD. Crystal Growth and Design, 2009, 9, 1869-1888. | 3.0 | 161 |
| 40 | Solubility Advantage of Pharmaceutical Cocrystals. Crystal Growth and Design, 2009, 9, 2252-2264. | 3.0 | 709 |
| 41 | Understanding and Predicting the Effect of Cocrystal Components and pH on Cocrystal Solubility. Crystal Growth and Design, 2009, 9, 3976-3988. | 3.0 | 147 |
| 42 | A rapid thermal method for cocrystal screening. CrystEngComm, 2008, 10, 665. | 2.6 | 259 |
| 43 | Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine. CrystEngComm, 2008, 10, 856. | 2.6 | 325 |
| 44 | pH-Induced Nanosegregation of Ritonavir to Lyotropic Liquid Crystal of Higher Solubility than Crystalline Polymorphs. Molecular Pharmaceutics, 2008, 5, 956-967. | 4.6 | 13 |
| 45 | Solvent Systems for Crystallization and Polymorph Selection. , 2007, , 53-109. | | 12 |
| 46 | Mechanisms by Which Moisture Generates Cocrystals. Molecular Pharmaceutics, 2007, 4, 360-372. | 4.6 | 115 |
| 47 | Cocrystals:â€‰ Molecular Design of Pharmaceutical Materials. Molecular Pharmaceutics, 2007, 4, 299-300. | 4.6 | 61 |
| 48 | Phase Solubility Diagrams of Cocrystals Are Explained by Solubility Product and Solution Complexation. Crystal Growth and Design, 2006, 6, 592-600. | 3.0 | 278 |
| 49 | Reaction Crystallization of Pharmaceutical Molecular Complexes. Molecular Pharmaceutics, 2006, 3, 362-367. | 4.6 | 263 |
| 50 | Cocrystal Formation during Cogrinding and Storage is Mediated by Amorphous Phase. Pharmaceutical Research, 2006, 23, 2381-2392. | 3.5 | 215 |
| 51 | General principles of pharmaceutical solid polymorphism A supramolecular perspective. Advanced Drug Delivery Reviews, 2004, 56, 241-274. | 13.7 | 373 |
| 52 | General Principles of Pharmaceutical Solid Polymorphism. A Supramolecular Perspective. ChemInform, 2004, 35, no. | 0.0 | 0 |
| 53 | Fourier transform infrared spectroscopy for the analysis of neutralizer-carbomer and surfactant-carbomer interactions in aqueous, hydroalcoholic, and anhydrous gel formulations. AAPS Journal, 2004, 6, 61-67. | 4.4 | 26 |
| 54 | Crystal Engineering of the Composition of Pharmaceutical Phases:â€‰ Multiple-Component Crystalline Solids Involving Carbamazepine. Crystal Growth and Design, 2003, 3, 909-919. | 3.0 | 493 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Effect of initial buffer composition on pH changes during far-from-equilibrium freezing of sodium phosphate buffer solutions. Pharmaceutical Research, 2001, 18, 90-97. | 3.5 | 143 |
| 56 | Growth and morphology of L-alanine crystals: influence of additive adsorption. Pharmaceutical Research, 1993, 10, 1008-1014. | 3.5 | 24 |
| 57 | NUCLEATION AND CRYSTAL GROWTH EFFECTS ON PARTICLE CHARACTERISTICS. Particulate Science and Technology, 1992, 10, 33-35. | 2.1 | 0 |
| 58 | Phase transition and heterogeneous/epitaxial nucleation of hydrated and anhydrous theophylline crystals. International Journal of Pharmaceutics, 1992, 85, 149-162. | 5.2 | 109 |
| 59 | Crystal growth kinetics of theophylline monohydrate. Pharmaceutical Research, 1991, 08, 643-648. | 3.5 | 23 |